《业绩》玮俊生物科技(00660.HK)全年亏损扩至4,421万元 股份复牌

阿斯达克财经
Dec 22, 2024

玮俊生物科技(00660.HK) 公布6月止财政年度业绩,收入录得3.7亿元,按年下降52.2%。亏损由上年度1,543万元,扩至4,421万元,每股亏损25.8仙。不派末期息。

过往派息
公布日期派息事项派息内容
2024/02/29中期业绩无派息
2023/09/29末期业绩无派息
2023/02/28中期业绩无派息
2023/01/10特别业绩合并:10股合并为1股

公司股份已申请周一(23日)起恢复买卖。(de/d)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10